ECE2022 Eposter Presentations Thyroid (219 abstracts)
1Casa di Cura Villa Berica, Endocrinology and Diabetology Service, Vicenza, Italy; 2Casa di Cura Villa Berica, Minimally Invasive Cancer Therapy Center, Vicenza, Italy
In recent years, US-guided thermal ablation techniques have been proposed as a therapeutic alternative to traditional surgery or to metabolic radiotherapy for thyroid nodes. RFA is one of the most used technique and experience in both ultrasound and ultrasound interventional is important for results and minimizing complications. We present our experience after 1 year of activity on the first 33 patients with thyroid nodules treated with RFA. The nodules were evaluated by ultrasound (Samsung RS85) and classified according to the TI-RADS criteria In all patients, 2 ultrasound-guided fine needle aspirations were performed at different points of the nodule according to guidelines. Thermoablation was performed under local anesthesia with Amica-Gen HS Hospital Service RF generator and 18G electrode needles with 7-10 mm exposed tip were used by moving shot method 33 patients were treated (9M; 24F); mean age 55.9 years (33-87); one session per patient. 25 cases presented compression symptoms; 3 cases progressive volumetric increase of the nodule at the controls; 5 cases cosmetic score equal to 4. Mean follow up 7.3 months (1-12) We have not seen any complications. The table lists the characteristics of the focal thyroid lesions, the sessions performed, and the preliminary results obtained (relative volume reduction, RVR, and effect on symptoms). A patient had a partial relapse of symptoms after 6 months and was referred for surgery. In our initial experience, the RF thermoablative treatment proved to be safe and effective and confirms what is reported in the literature data. The treatment must be preceded by adequate information on the modalities of the treatment session and the advantages and disadvantages of the procedure.
Volume Average (cc) | 27.7 (4.5 - 80) |
Right lobe | 17 (51.5%) |
Left lobe | 16 (48.5%) |
Ecostructure | isoechoic 3 (9.1%) |
hypoechoic 6 (18.2%) | |
hyperechoic 18 (54.5%) | |
mixed (solid-cystic) 6 (18.2%) | |
Vascularization | peripheral 21 (63.6%) |
peripheral + internal 12 (36.4%) | |
Cytology (2 FNAC) | TIR 2 + TIR 2 29 (87.9%) |
TIR 2 + TIR 3a 4 (12.1%) | |
RFA | |
Power (Watt) | 25-45 |
Average time | 15 48 (5 43" - 34 10") |
Average number of shots | 11 (5-18) |
RESULTS | |
RVR 1 week (33 pat.) | 15% (0-33%) |
RVR 1 month (33 pat.) | 32% (16-65%) |
RVR 6 months (27 pat.) | 54% (33-75%) |
RVR 1 year (6 pat) | 67% (51-75%) |
Reduction/resolution of symtoms (% pat.) 1 week 1 month 6 months | 56% 80% 96% |